Albuterol — Short-acting beta-2 adrenergic agonist (SABA). Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Albuterol
Class
Short-acting beta-2 adrenergic agonist (SABA)
Mechanism
Activates beta-2 receptors on airway smooth muscle, raising cyclic AMP via adenylcyclase and relaxing bronchial smooth muscle.
Used for
Bronchospasm treatment or prevention in reversible obstructive airway disease, aged 4 or older; Exercise-induced bronchospasm prevention, aged 4 or older
Beta-blockers; Non-potassium-sparing diuretics; MAO inhibitors, tricyclic antidepressants
Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.
Label date: 20260806 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
On both cards: Common side effects — Headache; Pharyngitis · Interactions — Beta-blockers
Only on the Fluticasone Propionate / Salmeterol card: Used for — Asthma maintenance from age 4 when an inhaled corticosteroid alone is inadequate or combined ICS/LABA therapy is warranted; COPD maintenance and exacerbation reduction with the specifically indicated DISKUS strength · Common side effects — Upper respiratory tract infection; Dysphonia; Oral candidiasis · Warnings — Not for acute bronchospasm; Pneumonia in COPD; Adrenal suppression / reduced bone density · Interactions — Strong CYP3A4 inhibitors; MAOIs / tricyclic antidepressants
Mechanism: A synthetic trifluorinated corticosteroid with anti-inflammatory activity. High glucocorticoid-receptor binding affinity is shown in vitro, but its clinical significance and the precise mechanism of rhinitis symptom relief are unknown.
On both cards: Common side effects — Headache; Pharyngitis
Only on the Fluticasone card: Used for — Nasal symptoms of perennial nonallergic rhinitis in adults and children aged 4 or older · Common side effects — Epistaxis; Nasal burning / irritation; Cough · Warnings — Epistaxis, nasal ulceration, septal perforation; Glaucoma and cataracts; Hypercorticism and adrenal suppression · Interactions — Strong CYP3A4 inhibitors (e.g. ritonavir, ketoconazole)
Mechanism: Binds with high affinity and selectivity to the CysLT1 receptor, inhibiting physiologic actions of leukotriene D4 in the airway.
On both cards: Common side effects — Headache; Pharyngitis
Only on the Montelukast card: Used for — Asthma prophylaxis and chronic treatment in patients aged 15 years and older; Prevention of exercise-induced bronchoconstriction in patients aged 15 years and older; Seasonal or perennial allergic rhinitis in patients aged 15 years and older only when alternative therapies are ineffective or not tolerated · Common side effects — Upper respiratory infection; Fever; Cough · Warnings — Not for acute asthma attacks; Systemic eosinophilia / Churg-Strauss; Aspirin sensitivity persists
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Capsera